Journal Mobile Options
Table of Contents
Vol. 14, No. 2, 2011
Issue release date: March 2011
Public Health Genomics 2011;14:96–103
(DOI:10.1159/000296278)

A European Survey on Biobanks: Trends and Issues

Zika E. · Paci D. · Braun A. · Rijkers-Defrasne S. · Deschênes M. · Fortier I. · Laage-Hellman J. · Scerri C.A. · Ibarreta D.
aEuropean Commission, Joint Research Centre, Institute for Prospective Technological Studies, Seville, Spain; bEuropean Research Council, Brussels, Belgium; cVDI-Technologiezentrum GmbH, Future Technologies Division, Düsseldorf, Germany; dPublic Population Project in Genomics (P3G), Montreal, Que.; eChalmers University of Technology and Institute for Management of Innovation and Technology, Gothenburg, Sweden; fMalta Council for Science & Technology, Kalkara, Malta

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Biobanks have recently gained great significance for research and personalised medicine, being recognised as a crucial infrastructure. At the same time, the widely varied practices in biobanking may also pose a barrier to cross-border research and collaboration by limiting access to samples and data. Nevertheless, the extent of the actual activities and the impact of the level of networking and harmonisation have not been fully assessed. To address these issues and to obtain missing knowledge on the extent of biobanking in Europe, the Institute for Prospective Technological Studies (IPTS) of the European Commission’s Joint Research Centre, in collaboration with the European Science and Technology Observatory (ESTO), conducted a survey among European biobanks. In total, 126 biobanks from 23 countries responded to the survey. Most of them are small or medium-sized public collections set up either for population-based or disease-specific research purposes. The survey indicated a limited networking among the infrastructures. The large majority of them are stand-alone collections and only about half indicated to have a policy for cross-border sharing of samples. Yet, scientific collaborations based on the use of each biobank appear to be prominent. Significant variability was found in terms of consent requirements and related procedures as well as for privacy and data protection issues among the biobanks surveyed. To help promote networking of biobanks and thus maximise public health benefits, at least some degree of harmonisation should be achieved.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Zika E, Gurwitz D, Ibarreta D: Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impact in the EU. European Commission DG JRC/IPTS, EUR 22214, 2006.
  2. Austin MA, Harding S, McElroy C: Genebanks: a comparison of eight proposed international genetic databases. Community Genet 2003;6:37–45.
  3. Yuille M, van Ommen G, Bréchot C, Cambon-Thomsen A, Dagher G, Landegren U, Litton J, Pasterk M, Peltonen L, Taussig M, Wichmann H, Zatloukal K: Biobanking for Europe. Brief Bioinform 2008;9:14–24.
  4. Burke W, Khoury MJ, Stewart A, Zimmern RL: The path from genome-based research to population health: development of an international public health genomics network. Genet Med 2006;8:451–458.
  5. Gwinn M, Bowen M, Khoury M: Genomics and public health at CDC. MMWR Morb Mortal Wkly Rep 2006;55(suppl 2):20–21.

    External Resources

  6. Khoury MJ, Millikan R, Little J, Gwinn M: The emergence of epidemiology in the genomics age. Int J Epidemiol 2004;33:936–944.
  7. Khoury MJ: The case for a global human genome epidemiology initiative. Nat Genet 2004;36:1027–1028.
  8. Burton PR, Hansell AL: Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol 2009;38:263–273.
  9. European Commission: Final Report on the Networking Meeting for EU-Funded Biobanking Projects. DG Research, Brussels, November 2008. Available at http://cordis.europa.eu/fp7/health/past-events_en.html.
  10. Liano F, Torres A: Biobanks: a new tool for clinical research. Nefrologia 2009;29:193–195.
  11. Zika E, Schulte in den Bäumen T, Kaye J, Brand A, Ibarreta D: Sample, data use and protection in biobanking in Europe: legal issues. Pharmacogenomics 2008;9:773–781.
  12. Hagen HE, Carlstedt-Duke J: Building global networks for human diseases: genes and populations. Nat Med 2004;10:665–667.
  13. OECD: Towards a global biological resource centre network. Paris, OECD, 2007.
  14. Public Population Projects in Genomics (P3G). Available at http://www.p3g.org.
  15. Knoppers BM, Fortier I, Legault D, Burton P: The Public Population Project in Genomics (P3G): a proof of concept? Eur J Hum Genet 2008;16:664–665.
  16. Hirtzlin I, Dubreuil C, Preaubert N, Duchier J, Jansen B, Simon J, Lobato De Faria P, Perez-Lezaun A, Visser B, Williams GD, Cambon-Thomsen A: An empirical survey on biobanking of human genetic material and data in six EU countries. Eur J Hum Genet 2003;11:475–488.
  17. National Biobank Network. Available at http://www.biobanks.hu.
  18. Andrews LB: Harnessing the Benefits of Biobanks. J Law Med Ethics 2005;33:22–30.
  19. Knoppers BM, Abdul-Rahman, Ma’n H, Bédard K: Genomic databases and international collaboration. Kings Law J 2007;18:291–311.
  20. Uranga AM, Arribas CM, Jaeger C, Posadas M: Outstanding legal and ethical issues on biobanks: an overview on the regulations of member states of the EuroBioBank project. Law Hum Genome Rev 2005;22:103–114.
  21. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Official Journal L 281, 23/11/1995 P. 0031–0050.
  22. Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM: Trends in ethical and legal frameworks for the use of human biobanks. Eur Respir J 2007;30:373–382.
  23. Joly Y, Knoppers BM: Pharmacogenomic data sample collection and storage: ethical issues and policy approaches. Pharmacogenomics 2006;7:219–226.
  24. Cambon-Thomsen A: Assessing the impact of biobanks. Nat Genet 2003;34:25–26.
  25. Riegman PH, Dinjens WN, Oosterhuis JW: Biobanking for interdisciplinary clinical research. Pathobiology 2007;74:239–244.
  26. Final Report of the joint PHOEBE – P3G – BBMRI Conference: Harmonising biobank research: maximising value – maximising use. Brussels, March 2009. Available at http://www.phoebe-eu.org/dav/2ecbab4a0f.pdf.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50